Influence of cytostatics on aggregation and adenine nucleotides of platelets.
D000227:Adenine Nucleotides / Q000378:metabolism*; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000578:Amidines / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D001761:Bleomycin / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002462:Cell Membrane / Q000187:drug effects; D003520:Cyclophosphamide / Q000494:pharmacology; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000494:pharmacology; D006037:Glyoxal / Q000494:pharmacology; D006801:Humans; D006835:Hydrazones / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D010973:Platelet Adhesiveness / Q000187:drug effects*; D014228:Triaziquone; D014748:Vinca Alkaloids / Q000494:pharmacology
D000227:Adenine Nucleotides; D000578:Amidines; D000970:Antineoplastic Agents; D006835:Hydrazones; D014748:Vinca Alkaloids; D001761:Bleomycin; D006037:Glyoxal; D000244:Adenosine Diphosphate; D003520:Cyclophosphamide; D014228:Triaziquone; D001241:Aspirin; D005472:Fluorouracil; D008727:Methotrexate